tiprankstipranks

Ryan Drant Insider Profile

4 Followers
Ryan Drant, Ten Percent Owner at Ardelyx, holds 7.49M shares in Ardelyx (Ticker: ARDX), holds 504.00 shares in Tesaro (Ticker: TSRO), holds 0.00 shares in Hyperion Therapeutics (Ticker: HPTX). Most recently, Ryan Drant Bought ― shares of Ardelyx on Jun 09, 2015 for an estimated value of 20.00M.
tipranks
Ryan Drant

Ryan Drant
Ardelyx (ARDX)
Ten Percent Owner

Ranked #10,888 out of 78,624 Corporate Insiders

Profitable Transactions

38%
20 out of 52 Profitable Transactions

Average Return

+5.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$83M
56.70%
20.01%
8.39%
5.92%
8.99% Others
A breakdown of Ryan Drant's holdings

Insider Roles

Ardelyx
(ARDX)
Ten Percent Owner
TRACON Pharmaceuticals
(TCON)
Ten Percent Owner
Sunesis Pharma
(SNSS)
Ten Percent Owner
Epizyme
(EPZM)
Ten Percent Owner
+6 other positions
Roles that Ryan Drant holds in companies

Most Profitable Insider Trade

Stock:
Groupon
(GRPN)
Rating:Informative Buy
Date:Nov 03, 2011 - Nov 03, 2012
Return:+283.00%
The most profitable trade made by Ryan Drant

Ryan Drant's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Ardelyx
Jun 09, 2015
Ten Percent Owner
Informative Buy
20.00M
$47.26M
DATA
Tableau
Dec 04, 2014
Uninformative Buy
$67.35M
TRACON Pharmaceuticals
Feb 05, 2015
Ten Percent Owner
Uninformative Buy
$16.68M
TRIV
Trivascular Technologies
Apr 24, 2014
Uninformative Buy
882.13K
$23.15M
Box
Jan 22, 2015
Ten Percent Owner
Informative Buy
$3.00M
TSRO
Tesaro
Jun 02, 2015
Uninformative Buy
$37.78K
HPTX
Hyperion Therapeutics
May 11, 2015
Uninformative Sell
109.69M
DERM
Dermira
Oct 08, 2014
Uninformative Buy
$65.68M
LOXO
Loxo Oncology
Aug 06, 2014
Uninformative Buy
$419.91M
HIVE
Aerohive Networks
Apr 03, 2014
Uninformative Buy
$20.75M
CRCM
Care
Jan 29, 2014
Uninformative Buy
$48.84M
MM
Millennial Media
Oct 30, 2012
Informative Sell
21.47M
$14.34M
Epizyme
Aug 18, 2014
Ten Percent Owner
Uninformative Buy
$4.93M
ROKA
Sorrento Tech Inc
Jul 22, 2014
Uninformative Buy
$2.09M
Sunesis Pharma
Aug 29, 2014
Ten Percent Owner
Informative Sell
2.13M
$6.99M
Workday
Apr 11, 2013
Ten Percent Owner
Uninformative Buy
$2.79M
Clovis Oncology
Jun 05, 2013
Ten Percent Owner
Uninformative Buy
$13.73K
Groupon
Sep 17, 2013
Ten Percent Owner
Uninformative Buy
$1.65M
XOOM
Xoom Corp
Oct 31, 2013
Uninformative Buy
INWK
InnerWorkings
Mar 30, 2012
Uninformative Buy
$45.94K
Echo Global Logistics
Mar 01, 2012
Ten Percent Owner
Uninformative Buy
$32.87K
ADNC
Audience Inc
Nov 06, 2013
Uninformative Buy
FIO
Fusion-IO
Jun 07, 2011
Informative Buy
OMTH
Omthera
ChannelAdvisor
Ten Percent Owner
$0.00
List of latest transactions for each holding click on a transaction to see Ryan Drant's performance on stock

Ryan Drant insider profile FAQ

What is the percentage of profitable transactions made by Ryan Drant?
The percentage of profitable transactions made by Ryan Drant is 38%.
    What is the average return per transaction made by Ryan Drant?
    The average return per transaction made by Ryan Drant is 5.10%.
      What stocks does Ryan Drant hold?
      Ryan Drant holds: ARDX, DATA, TCON, TRIV, BOX, TSRO, HPTX, DERM, LOXO, HIVE, CRCM, MM, EPZM, ROKA, SNSS, WDAY, CLVS, GRPN, XOOM, INWK, ECHO, ADNC, FIO, OMTH, ECOM stocks.
        What was Ryan Drant’s latest transaction?
        Ryan Drant latest transaction was an Informative Buy of $20.00M.
          What was Ryan Drant's most profitable transaction?
          Ryan Drant’s most profitable transaction was an Informative Buy of GRPN stock on November 3, 2011. The return on the trade was 283.00%.
            What is Ryan Drant's role in Ardelyx?
            Ryan Drant's role in Ardelyx is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.